衰老相关分泌表型因子在糖尿病衰老干预疗法中的研究进展

doi:10.3969/j.issn.1003-9198.2023.05.023

摘要/Abstract

中图分类号:

R 587.1

刘童君, 赵雅洁, 胡洁玲, 梁伟. 衰老相关分泌表型因子在糖尿病衰老干预疗法中的研究进展[J]. 实用老年医学, 2023, 37(5): 528-531.

[1] COPPÉ J P, DESPREZ P Y, KRTOLICA A,et al. The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol, 2010,5:99-118.
[2] MYRIANTHOPOULOS V, EVANGELOU K, VASILEIOU P V S, et al.Senescence and senotherapeutics: a new field in cancer therapy[J]. Pharmacol Ther, 2019, 193:31-49.
[3] THOMPSON PJ, SHAH A, NTRANOS V, et al. Targeted elimination of senescent beta cells prevents type 1 diabetes[J]. Cell Metab, 2019,29(5):1045-1060.e10.
[4] AGUAYO-MAZZUCATO C, ANDLE J, LEE Jr T B, et al. Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes[J]. Cell Metab, 2019,30(1):129-142.e4.
[5] MUÑOZ-ESPÍN D, SERRANO M.Cellular senescence: from physiology to pathology[J]. Nat Rev Mol Cell Biol, 2014,15(7):482-496.
[6] NGCOBO S R, NKAMBULE B B, NYAMBUYA T M, et al. Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: a systematic review of preclinical and clinical studies[J]. Biomed Pharmacother, 2022,146:112579.
[7] AL-MANSOORI L, AL-JABER H, PRINCE M S, et al. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance[J]. Inflammation, 2022,45(1):31-44.
[8] CHYLIKOVA J, DVORACKOVA J, TAUBER Z, et al. M1/M2 macrophage polarization in human obese adipose tissue[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(2):79-82.
[9] BALLAK D B, STIENSTRA R, TACK C J, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance[J]. Cytokine, 2015, 75(2):280-290.
[10] ZATTERALE F, LONGO M, NADERI J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes[J]. Front Physiol, 2020,10:1607.
[11] ENGIN A B. Adipocyte-macrophage cross-talk in obesity[J]. Adv Exp Med Biol, 2017,960:327-343.
[12] SINGH S, ANSHITA D, RAVICHANDIRAN V. MCP-1: function, regulation, and involvement in disease[J]. Int Immunopharmacol, 2021,101(Pt B):107598.
[13] HUANG Y T, LIU C H, YANG Y C, et al. ROS- and HIF1α-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis[J]. J Cell Physiol, 2019,234(8):13557-13570.
[14] HAYWOOD N J, SLATER T A, MATTHEWS C J, et al. The insulin like growth factor and binding protein family: novel therapeutic targets in obesity & diabetes[J]. Mol Metab, 2019, 19:86-96.
[15] HU B A, SAI W W, YUAN J, et al. PGF2α-FP receptor ameliorates senescence of VSMCs in vascular remodeling by Src/PAI-1 signal pathway[J]. Oxid Med Cell Longev, 2022.DOI: 10.1155/2022/2908261.
[16] GUHA N, NEVITT S P, FRANCIS M, et al. The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes[J]. Clin Endocrinol: Oxf, 2021, 94(4):551-562.
[17] ESPOSITO P, VERZOLA D, PICCIOTTO D, et al. Myostatin/activin-A signaling in the vessel wall and vascular calcification[J]. Cells, 2021,10(8):2070.
[18] ROH J D, HOBSON R, CHAUDHARI V, et al. Activin type II receptor signaling in cardiac aging and heart failure[J]. Sci Transl Med, 2019,11(482):eaau8680.
[19] CHANG S C, HSU C Y, LIU L K, et al. The association between serum activin A levels and albuminuria among community-dwelling middle-aged and older adults in Taiwan[J]. Sci Rep, 2021,11(1):20032.
[20] BLUMENSATT M, GREULICH S, HERZFELD DE WIZA D, et al. Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143[J]. Cardiovasc Res, 2013,100(2):201-210.
[21] UNGERLEIDER N A, BONOMI L M, BROWN M L, et al. Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice[J]. Endocrinology, 2013, 154(6):2025-2033.
[22] WANG H L, WEI B, HE H J, et al. Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferationviathe E2F3-dependent mechanism[J]. Theranostics, 2022, 12(1):379-395.
[23] CAO E, WATT M J, NOWELL C J, et al. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity[J]. Nat Metab, 2021, 3(9):1175-1188.
[24] INOUE H, HANAWA N, KATSUMATA-TSUBOI R, et al. Down-regulation of senescence marker protein 30 by iron-specific chelator deferoxamine drives cell senescence[J]. Biosci Biotechnol Biochem, 2018, 82(5):900-903.
[25] JIN C, WU P, LI L,et al. Exosomes: emerging therapy delivery tools and biomarkers for kidney diseases[J]. Stem Cells Int, 2021.DOI: 10.1155/2021/7844455.
[26] ZUBIRI I, POSADA-AYALA M, BENITO-MARTIN A, et al. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes[J]. Transl Res, 2015, 166(5):474-484.e4.
[27] ZHANG L, ZHU T, HE F, et al. Senescence marker protein 30(SMP30) protects against high glucose-induced apoptosis, oxidative stress and inflammatory response in retinal ganglion cells by enhancing Nrf2 activation via regulation of Akt/GSK-3β pathway[J]. Int Immunopharmacol, 2021,101(Pt B):108238.
[28] ZHANG B, CUI S, BAI X, et al. SIRT3 overexpression antagonizes high glucose accelerated cellular senescence in human diploid fibroblasts via the SIRT3-FOXO1 signaling pathway[J]. Age: Dordr, 2013, 35(6):2237-2253.
[29] D'MARCO L, MORILLO V, GORRIZ J L, et al. SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence[J]. J Diabetes Res, 2021. DOI: 10.1155/2021/9032378.
[30] WU W C, LEE W J, LEE T H, et al. Do different bariatric surgical procedures influence plasma levels of matrix metalloproteinase-2, -7, and -9 among patients with type 2 diabetes mellitus?[J]. World J Diabetes, 2020,11(6):252-260.
[31] LÓPEZ-OTÍN C, BLASCO M A, PARTRIDGE L, et al. The hallmarks of aging[J]. Cell, 2013,153(6):1194-1217.
[32] KHOSLA S, FARR J N, TCHKONIA T, et al. The role of cellular senescence in ageing and endocrine disease[J]. Nat Rev Endocrinol, 2020,16(5):263-275.
[33] RUSSELL-JONES D, POUWER F, KHUNTI K. Identification of barriers to insulin therapy and approaches to overcoming them[J]. Diabetes Obes Metab, 2018, 20(3):488-496.

衰老相关分泌表型因子在糖尿病衰老干预疗法中的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	王苏, 赵一璟, 魏晨敏, 陈堃, 曹雯, 王昆, 杨昱. 老年T2DM病人甘油三酯葡萄糖指数与低密度脂蛋白亚型的关系研究[J]. 实用老年医学, 2024, 38(10): 1002-1006.
[2]	顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029.
[3]	周潇, 顾荣, 孔小岑, 罗勇, 王蔚萍, 马建华, 李惠琴. 桑枝总生物碱和卡格列净治疗血糖控制不佳的老年2型糖尿病病人的疗效观察[J]. 实用老年医学, 2024, 38(10): 1066-1069.
[4]	刘倩慧, 姚子俊, 何玉立, 徐云凡, 吴军. 老年2型糖尿病合并慢性心力衰竭病人HbA1c水平对心脏结构和功能的影响[J]. 实用老年医学, 2024, 38(5): 491-437.
[5]	刘童君, 赵雅洁, 胡洁玲, 胡洋, 梁伟. 糖代谢异常对血清激活素A水平的影响[J]. 实用老年医学, 2024, 38(5): 495-437.
[6]	杨龙璇, 唐伟. 细胞衰老与2型糖尿病胰岛B细胞功能障碍的研究进展[J]. 实用老年医学, 2024, 38(5): 521-437.
[7]	王金涛, 胡坚. 老年人2型糖尿病与肌少症的关系研究进展[J]. 实用老年医学, 2024, 38(5): 529-437.
[8]	唐源, 邓暑芳, 何咏梅, 戴雨璇, 罗晶. 老年2型糖尿病病人健康素养水平及其与衰弱的相关性[J]. 实用老年医学, 2024, 38(3): 255-259.
[9]	代玲俐, 俞匀. 老年2型糖尿病病人估计肾小球滤过率与胰岛素抵抗及胰岛B细胞功能的相关性研究[J]. 实用老年医学, 2023, 37(12): 1219-1223.
[10]	范婷泳, 袁丽, 杨小玲, 陈茜. Caprini量表评估老年糖尿病病人静脉血栓栓塞症的效果[J]. 实用老年医学, 2023, 37(12): 1233-1237.
[11]	张贺成, 魏苏. 老年2型糖尿病病人血清铁蛋白水平与糖尿病足发生的相关性[J]. 实用老年医学, 2023, 37(11): 1111-1114.
[12]	胡艳, 巫海娣, 王雪菲, 娄青林, 叶青, 顾刘宝, 戴静, 宋小波. 老年2型糖尿病病人糖尿病足风险评分与尿微量白蛋白/肌酐的相关性分析[J]. 实用老年医学, 2023, 37(11): 1134-1137.
[13]	宗前兴, 莫永珍. 老年2型糖尿病健康状态分层框架的应用与研究进展[J]. 实用老年医学, 2023, 37(11): 1170-1175.
[14]	张林英, 梅群超, 张炜琦, 胡一兰. 抗阻训练联合高乳蛋白营养在老年2型糖尿病伴肌少症病人中的应用研究[J]. 实用老年医学, 2023, 37(10): 995-999.
[15]	刘倩慧, 姚子俊, 何玉立, 吴军. SGLT2i对老年糖尿病病人心血管保护机制的研究进展[J]. 实用老年医学, 2023, 37(10): 1064-1068.